Moxisylyte
Basic information
- CAS
54-32-0- Standard SMILES
CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C- InChIKey
VRYMTAVOXVTQEF-UHFFFAOYSA-N- Molecular formula
- C16H25NO3
- Average molar mass
- 279.37 g/mol
- Monoisotopic mass
- 279.18344366
Overview
Acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester is a monoterpenoid.
Names & identifiers
- Preferred name
- Moxisylyte
- IUPAC
- [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] acetate
- English name
- MOXISYLYTE
- Molecular formula
- C16H25NO3
- Molecular weight
- 279.37
Names & synonyms
MoxisylyteThymoxamine54-32-0CarlyteneMoxisilitaAcetoxythymoxamineMoxisylytumPW8QYA7KI0(2-(4-Acetoxy-2-isopropyl-5-methylphenoxy)ethyl)dimethylamine6-Acetoxythymol 2-(dimethylamino)ethyl etherDTXSID40233394-[2-(dimethylamino)ethoxy]-2-methyl-5-(propan-2-yl)phenyl acetate
Show more names
sympalopilonVasoklinarlytenemoxilitemoxisylyttimoxaminaTHYMOXAMINE HCL
ThymoxyalcylaminemoxisiliteErecnos4-(2-(dimethylamino)ethoxy)-2-methyl-5-(propan-2-yl)phenyl acetateRefChem:159852DTXCID403339C04AX10G04BE06
Database identifiers
- CAS
54-32-0、964-52-3- PubChem CID
- 4260
- DTXSID
DTXSID4023339- ChEMBL
CHEMBL159226- ChEBI
CHEBI:94754- UNII
- PW8QYA7KI0
- EC Number
- 200-204-1
- Nikkaji
- J4.154H
Properties
Computed structural properties
- XLogP
- 3.2
- Topological polar surface area
- 38.8 Ų
- Hydrogen bond donors
- 0
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 7
- Heavy atoms
- 20
- Formal charge
- 0
- Complexity
- 304
Experimental & physicochemical properties
DrugsPharmaceuticals -> Listed in ZINC15
LogP3.17
Solubility>47.4 ug/ml
Boiling Point371ºC at 760 mmHg
Melting Point145ºC
Dissociation Constants8.71
Physicochemical properties
- storage temp.
- 2 · 2-8°C
- FDA UNII
- 8 QYA7KI0 · PW8QYA7KI0
- ATC code
- 4 AX10,G04BE06 · C04AX10,G04BE06
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302-H315-H319-H335
- Precautionary statements
- 261 · P261-P305+P351+P338
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Hazard information
Other Safety InformationIMAP assessments - Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester): Human health tier I assessment
Toxicology
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Moxisylyte
vMost-DILI-concern
8
Withdrawn
DOI:10.1016/j.drudis.2016.02.015
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H302-H315-H319-H335
- Precautionary statements
- P261-P305+P351+P338
Chemistry & industry
Pharmacology
ATC Code
G - Genito urinary system and sex hormones
C - Cardiovascular system
QG - Genito urinary system and sex hormones
QC - Cardiovascular system
Pharmacodynamics
Administration of moxisylyte has shown to improve peripheral flow in occlusive arterial disease with little effect in blood pressure. There are reports of increases in cutaneous blood flow and skin temperature after local application of moxisylyte.
Mechanism of ActionMoxisylyte is vasodilator that works as a specific alpha-adrenergic blocking agent. Its action is known to be competitive against norepinephrine without beta-receptor blocking, anti-angiotensin or anti-serotonin activity.
Biological Half-LifeThe half-life of moxisylyte was of 1-2 hours.
Metabolism/Metabolites
The pharmacokinetic profile of moxisylyte can make this drug to be considered as a prodrug as its biotransformation is very rapid. This drug gets rapidly hydrolyzed by pseudocholinesterase in plasma and tissues to give the major metabolite deacetyl-thymoxamine. This first metabolite is later demethylated by the cytochrome P450 monooxygenase system to form deacetyl-demethyl-thymoxamine. Both of this major metabolites are pharmacologically active. The pharmacokinetic studies with moxisylyte in urine and feces have shown the presence of 8 different metabolites, where two of them are highly polar and resistant to enzymatic hydrolysis. From this metabolites, it has been detected the sulfate and glucuronide conjugates of the major metabolites.
MeSH Pharmacological Classification
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here.
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…